Merck CEO warns Congress that restricting US-China biotech deals could cost America its biotech leadership

Merck CEO Rob Davis told Congress and the Trump administration that limiting or cutting off US-China dealmaking would jeopardize US biotech leadership.

He emphasized that collaboration with Chinese partners has been crucial for developing and licensing molecules, and that restrictions could hinder innovation and market access.

Davis cautioned that such policy moves could cause the United States to fall behind globally in biotech, urging lawmakers to consider the long-term impact on the industry.